| Unlocking the potential of antibody–drug conjugates for cancer therapy JZ Drago, S Modi, S Chandarlapaty Nature Reviews Clinical Oncology 18 (6), 327-344, 2021 | 645 | 2021 |
| Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions E Ferraro, JZ Drago, S Modi Breast Cancer Research 23 (1), 84, 2021 | 158 | 2021 |
| FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer JZ Drago, L Formisano, D Juric, A Niemierko, A Servetto, SA Wander, ... Clinical Cancer Research 25 (21), 6443-6451, 2019 | 75 | 2019 |
| Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study JZ Drago, D Lawrence, E Livingstone, L Zimmer, T Chen, ... Melanoma research 29 (1), 65-69, 2019 | 33 | 2019 |
| Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance A Safonov, C Bandlamudi, PT de Lara, E Ferraro, F Derakhshan, M Will, ... Cancer Research 82 (4_Supplement), GS4-08-GS4-08, 2022 | 25 | 2022 |
| A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer K Jhaveri, JZ Drago, PD Shah, R Wang, F Pareja, F Ratzon, A Iasonos, ... Clinical Cancer Research 27 (14), 3867-3875, 2021 | 22 | 2021 |
| Beyond HER2: targeting the ErbB receptor family in breast cancer JZ Drago, E Ferraro, N Abuhadra, S Modi Cancer treatment reviews 109, 102436, 2022 | 21 | 2022 |
| Targeting apoptosis: a new paradigm for the treatment of estrogen receptor–positive breast cancer JZ Drago, S Chandarlapaty, K Jhaveri Cancer Discovery 9 (3), 323-325, 2019 | 18 | 2019 |
| Inferences about drug safety in phase III trials in oncology: examples from advanced prostate cancer JZ Drago, M Gönen, G Thanarajasingam, CA Sacks, MJ Morris, ... JNCI: Journal of the National Cancer Institute 113 (5), 553-561, 2021 | 17 | 2021 |
| Morphologic and genomic characteristics of breast cancers occurring in individuals with Lynch syndrome CJ Schwartz, EM da Silva, A Marra, AM Gazzo, P Selenica, VK Rai, ... Clinical Cancer Research 28 (2), 404-413, 2022 | 16 | 2022 |
| The harm in kratom JZ Drago, B Lane, J Kochav, B Chabner The Oncologist 22 (8), 1010-1011, 2017 | 12 | 2017 |
| Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest? JZ Drago, PW Kantoff, KH Stopsack Journal of Clinical Oncology 38 (6_suppl), 318-318, 2020 | 9 | 2020 |
| FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer. JZ Drago, A Niemierko, L Spring, B Moy, D Juric, SJ Isakoff, AJ Iafrate, ... Journal of Clinical Oncology 35 (15_suppl), 1013-1013, 2017 | 7 | 2017 |
| Abstract HER2-07: HER2-07 Genomic Characterization of Primary and Metastatic HER2-low Breast Cancers A Marra, A Safonov, J Drago, E Ferraro, P Selenica, A Gazzo, ... Cancer Research 83 (5_Supplement), HER2-07-HER2-07, 2023 | 6 | 2023 |
| Abstract P2-09-03: Quantification of HER2 expression and spatial biology using computational pathology: A cross-assay validation study in breast cancer J Drago, Z Hassan, J Zaucha, A Kapil, F Derakhshan, F Pareja, S Anatoliy, ... Cancer Research 83 (5_Supplement), P2-09-03-P2-09-03, 2023 | 2 | 2023 |
| Buprenorphine Treatment for Opioid Addiction in the Primary Care Setting: Predictors of Treatment Success and Failure JZ Drago Harvard University, 2015 | 2 | 2015 |
| Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis NS Moss, JM Singh, AS Reiner, JZ Drago, S Modi, AD Seidman, ... NPJ Breast Cancer 9 (1), 86, 2023 | 1 | 2023 |
| HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers. JZ Drago, F Pareja, KL Jhaveri, EM Walsh, GY Ku, SB Maron, ... Journal of Clinical Oncology 41 (16_suppl), 1052-1052, 2023 | 1 | 2023 |
| ADCs or: how I learned to stop worrying and love chemotherapy A Gupta, JZ Drago, S Chandarlapaty Cancer Discovery 13 (4), 817-818, 2023 | 1 | 2023 |
| Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1 S Hurvitz, K Kalinsky, V Ganju, K Ali, L Agrawal, W Gradishar, G Sledge, ... Cancer Research 83 (5_Supplement), PD18-09-PD18-09, 2023 | 1 | 2023 |
